<DOC>
	<DOCNO>NCT03042299</DOCNO>
	<brief_summary>The purpose study evaluate bio-equivalence single oral administration TAK-536 pediatric formulation ( granule ) comparison TAK-536 commercial formulation Japanese healthy adult male participant open label , 2-period , 2-treatment , cross-over design .</brief_summary>
	<brief_title>A Phase 1 , Bio-equivalence Study TAK-536 Pediatric Formulation</brief_title>
	<detailed_description>The purpose study evaluate bio-equivalence single oral administration TAK-536 pediatric formulation ( granule ) comparison TAK-536 commercial formulation healthy adult male participant open label , 2-period , 2-treatment , cross-over design .</detailed_description>
	<criteria>1 . In opinion investigator subinvestigator , participant capable understand comply protocol requirement . 2 . The participant sign date write , informed consent form prior initiation study procedure . 3 . The participant Japanese healthy adult male . 4 . The participant age 20 35 year , inclusive , time informed consent . 5 . The participant weighs least 50.0 kg , body mass index ( BMI ) 18.5 25.0 kg/m^2 , inclusive , Screening . 1 . The participant suspect hypotension associate physical finding , dizziness postural , facial pallor , cold sweat base evaluation/physical examination Screening , day study drug administration ( Day 1 ) Period 1 , study drug administration Period 1 . 2 . The participant receive study drug within 16 week ( 112 day ) prior study drug administration Period 1 . 3 . The participant receive TAK536 TAK491 previous clinical study therapeutic agent . 4 . The participant uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , endocrine disease abnormality , may impact ability participant participate potentially confound study result . 5 . The participant know hypersensitivity component formulation TAK536 ARB . 6 . The participant positive urine drug result drug abuse ( define illicit drug use ) Screening . 7 . The participant history drug abuse ( define illicit drug use ) history alcohol abuse within 2 year prior Screening visit unwilling agree abstain alcohol drug throughout study . 8 . The participant take excluded medication , supplement , dietary product , food product time period list table . 9 . The participant current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( ie , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn , surgical intervention ) . 10 . The participant history cancer , except basal cell carcinoma remission least 5 year prior Day 1 Period 1 . 11 . The participant positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody/antigen , serological reaction syphilis Screening . 12 . The participant poor peripheral venous access . 13 . The participant undergone whole blood collection least 200 mL within 4 week ( 28 day ) least 400 mL within 12 week ( 84 day ) prior start study drug administration Period 1 . 14 . The participant undergone whole blood collection least 800 mL total within 52 week ( 364 day ) prior start study drug administration Period 1 . 15 . The participant undergone blood component collection within 2 week ( 14 day ) prior start study drug administration Period 1 . 16 . The participant abnormal ( clinically significant ) ECG Screening prior study drug administration Period 1 . 17 . The participant abnormal laboratory value suggest clinically significant underlying disease , participant follow laboratory abnormality Screening prior study drug administration Period 1 : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 1.5Ã—the upper limit normal ( ULN ) . 18 . The participant , opinion investigator subinvestigator , unlikely comply protocol unsuitable reason .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>